Choline analogues in malaria chemotherapy

Current Pharmaceutical Design

Volumn 18, Issue 24, 2012, Pages 3454-3466

  Peyrottes, Suzanne ^a   Caldarelli, Sergio ^a   Wein, Sharon ^b   Périgaud, Christian ^a   Pellet, Alain ^c   Vial, Henri ^b  

^a UNIVERSITÉ DE MONTPELLIER   (France)

^b UNIVERSITÉ DE MONTPELLIER   (France)

^c SANOFI   (France)

Author keywords

Choline analogues; Malaria; Pharmacology; Phospholipid; Plasmodium; Quaternary ammonium; Thiazolium salts

Indexed keywords

ALBITIAZOLIUM BROMIDE; AMMONIUM DERIVATIVE; ANTIMALARIAL AGENT; BIS(QUATERNARY AMMONIUM) DERIVATIVE; CHLOROQUINE; CHOLINE DERIVATIVE; PHOSPHOLIPID; UNCLASSIFIED DRUG;

CHEMOTHERAPY; DRUG DELIVERY SYSTEM; DRUG STRUCTURE; HYDROPHOBICITY; IC 50; IN VITRO STUDY; IN VIVO STUDY; MALARIA; MEDICAL LITERATURE; NONHUMAN; PHARMACOPHORE; PHOSPHOLIPID METABOLISM; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; REVIEW;

EID: 84867569846     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212801327338     Document Type: Review

References (41)

1. Roll Back malaria, The Global Malaria Action Plan for a malariafree world. Geneva, Switzerland, 2008; http://www.rollbackmalaria.org/gmap/index.html.
2. World malaria Report, World Health Organization. Geneva, Switzerland, 2010; http://www.who.int/malaria/world_malaria_report_2010/en/index.html.
3. Olliaro P, Wells TNC. The Global Portfolio of New Antimalarial Medicines Under Development. Clin. Pharmacol. Ther 2009; 85: 584-95.
4. Wells TN, Poll EM. When is enough enough? The need for a robust pipeline of high-quality antimalarials. Discovery Medicine 2010; 9: 389-98.
5. Carrara VI, Zwang J, Ashley EA, et al. Changes in the Treatment Responses to Artesunate-Mefloquine on the Northwestern Border of Thailand during 13 Years of Continuous Deployment. Plos One 2009; 4: e4551.
6. Dondorp AM, Yeung S, White L, et al. Artemisinin resistance: current status and scenarios for containment. Nat Rev Microbiol 2010; 8: 272-80.
7. Vial HJ, Penarete D, Wein S, et al. Apicomplexan Parasites: Molecular Approaches toward Targeted Drug Development Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, Germany, 2011; pp. 544.
8. Vial H, Calas M. Inhibitors of Phospholipid Metabolism in Antimalarial Chemotherapy, mechanims of action, modes of resistance, and new directions in drug development. The Humana Press Inc 2000: 347-65.
9. Dechamps S, Shastri S, Wengelnik K, Vial HJ. Glycerophospholipid acquisition in Plasmodium - a puzzling assembly of biosynthetic pathways. Int J Parasitol 2010; 40: 1347-65.
10. Vial HJ, Ancelin ML. In: Avila JL, Harris JR, Eds. Subcellular Biochemistry. Plenum Press: New York, NY, Etats-Unis, 1992; pp. 259-306.
11. Ancelin ML, Vial HJ. Regulation of phosphatidylcholine biosynthesis in Plasmodium-infected erythrocytes. Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism 1989; 1001: 82-9.
12. Calas M, Cordina G, Bompart J, et al. Antimalarial activity of molecules interfering with Plasmodium falciparum phospholipid metabolism. Structure-activity relationship analysis. J Med Chem 1997; 40: 3557-66.
13. Vial HJ, Thuet MJ, Ancelin ML, Philippot JR, Chavis C. Phospholipid metabolism as a new target for malaria chemotherapy. Mechanism of action of D-2-amino-1-butanol. Biochem Pharmacol 1984; 33: 2761-70.
14. Ancelin ML, Vial HJ. Quaternary ammonium compounds efficiently inhibit Plasmodium falciparum growth in vitro by impairment of choline transport. Antimicrob Agents Chemother 1986; 29: 814-20.
15. Calas M, Ancelin ML, Cordina G, et al. Antimalarial activity of compounds interfering with Plasmodium falciparum phospholipid metabolism: Comparison between monoand bisquaternary ammonium salts. J Med Chem 2000; 43: 505-16.
16. Kaur K, Jain M, Reddy RP, Jain R. Quinolines and structurally related heterocycles as antimalarials. Eur J Med Chem 2010; 45: 3245-64.
17. Biot C, Nosten F, Fraisse L, Ter-Minassian D, Khalife J, Dive D. The antimalarial ferroquine: from bench to clinic. Parasite 2011; 18: 207-14.
18. Burrows JN, Chibale K, Wells TNC. The State of the Art in Anti-Malarial Drug Discovery and Development. Curr Top Med Chem 2011; 11: 1226-54.
19. Peters W. In: Peters W, Richards WHG, Eds. Handbook of Experimental Pharmacology. Springer-Verlag, Berlin, 1984; pp. 484.
20. deVries PJ, Dien TK. Clinical pharmacology and therapeutic potential of artemisinin and its derivatives in the treatment of malaria. Drugs 1996; 52: 818-36.
21. Ancelin ML, Calas M, Vidal-Sailhan V, Herbute S, Ringwald P, Vial HJ. Potent inhibitors of Plasmodium phospholipid metabolism with a broad spectrum of in vitro antimalarial activities. Antimicrob Agents Chemother 2003; 47: 2590-7.
22. Roggero R, Zufferey R, Minca M, et al. Unraveling the Mode of Action of the Antimalarial Choline Analog G25 in Plasmodium falciparum and Saccharomyces cerevisiae. Antimicrob Agents Chemother 2004; 48: 2816-24.
23. Ancelin ML, Calas M, Bompart J, et al. Antimalarial activity of 77 phospholipid polar head analogs: Close correlation between inhibition of phospholipid metabolism and in vitro Plasmodium falciparum growth. Blood 1998; 91: 1426-37.
24. Wengelnik K, Vidal V, Ancelin ML, et al. A class of potent antimalarials and their specific accumulation in infected erythrocytes. Science 2002; 295: 1311-4.
25. Cheng Y, Prusoff WH. Relationship between inhibition constant (K1) and concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic-reaction. Biochem Pharmacol 1973; 22: 3099-108.
26. Ancelin ML, Calas M, Bonhoure A, Herbute S, Vial HJ. In vivo antimalarial activities of monoand bis quaternary ammonium salts interfering with Plasmodium phospholipid metabolism. Antimicrob Agents Chemother 2003; 47: 2598-605.
27. Beautelafitte A, Altemayercaillard V, Gonnetgonzalez F, Ramiaramanana L, Chabaud AG, Landau I. The chemosensitivity of the rodent malarias relationships with the biology of merozoites. Int J Parasitol 1994; 24: 981-6.
28. Landau I, Gautret P. In: Sherman IW, Ed. Malaria: Parasite Biology, Pathogenesis, and Protection. Am Soc Microbiol, Washington, DC, 1998; pp. 401-17.
29. Greb A, Bitsch R. Comparative bioavailability of various thiamine derivatives after oral administration. Int J Clin Pharm Th 1998; 36: 216-21.
30. Kawasaki C. Modified Thiamine Compounds. Vitam Horm 1963; 21: 69-111.
31. Thomson AD, Frank O, Baker H, Leevy CM. Thiamine propyl disulfide - absorption and utilization. Annals of Internal Medicine 1971; 74: 529-34.
32. Hamze A, Rubi E, Arnal P, et al. Monoand bis-thiazolium salts have potent antimalarial activity. J Med Chem 2005; 48: 3639-43.
33. Vial HJ, Wein S, Farenc C, et al. Prodrugs of bisthiazolium salts are orally potent antimalarials. Proc Nat Acad Sci USA 2004; 101: 15458-63.
34. Eastman RT, Fidock DA. Artemisinin-based combination therapies: a vital tool in efforts to eliminate malaria. Nature Reviews Microbiology 2009; 7: 864-74.
35. Richier E, Biagini GA, Wein S, et al. Potent antihematozoan activity of novel bisthiazolium drug T16: evidence for inhibition of phosphatidylcholine metabolism in erythrocytes infected with Babesia and Plasmodium spp. Antimicrob Agents Chemother 2006; 50: 3381-8.
36. Biagini GA, Richier E, Bray PG, Calas M, Vial H, Ward SA. Heme binding contributes to antimalarial activity of bis-quaternary ammoniums. Antimicrob Agents Chemother 2003; 47: 2584-9.
37. Caldarelli SA, Boisbrun M, Alarcon K, et al. Exploration of potential prodrug approach of the bis-thiazolium salts T3 and T4 for orally delivered antimalarials. Bioorg Med Chem Lett 2010; 20: 3953-6.
38. Salom-Roig XJ, Hamze A, Calas M, Vial HJ. Dual molecules as new antimalarials. Comb Chem High T Scr 2005; 8: 49-62.
39. Caldarelli S, Duckert JF, Wein S, et al. Synthesis and Evaluation of Bis-Thiazolium Salts as Potential Antimalarial Drugs. Chemmedchem 2010; 5: 1102-9.
40. Vial H, Mamoun C. In: Sherman I, Ed, Ed. Molecular Approach to Malaria. ASM Press: Washington DC, 2005; pp. 327-52.
41. Dechamps S, Wengelnik K, Berry-Sterkers L, Cerdan R, Vial HJ, Gannoun-Zaki L. The Kennedy phospholipid biosynthesis pathways are refractory to genetic disruption in Plasmodium berghei and therefore appear essential in blood stages. Mol Biochem Parasitol 2010; 173: 69-80.